339 related articles for article (PubMed ID: 15583654)
41. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
Tanaka M; Nagata T
Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
[TBL] [Abstract][Full Text] [Related]
42. Market watch: upcoming market catalysts in Q2 2011.
Jeng R
Nat Rev Drug Discov; 2011 Apr; 10(4):248. PubMed ID: 21455226
[No Abstract] [Full Text] [Related]
43. Sandoz sues FDA over delay in first biogeneric approval.
Fox JL
Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
[No Abstract] [Full Text] [Related]
44. Japan unveils 5-year plan to boost clinical research.
McCurry J
Lancet; 2007 Apr; 369(9570):1333-6. PubMed ID: 17455378
[No Abstract] [Full Text] [Related]
45. A forensic analysis of drug targets from 2000 through 2012.
Munos B
Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
[TBL] [Abstract][Full Text] [Related]
46. Aggressive drug marketing tactics trigger backlash.
Singer E
Nat Med; 2007 Apr; 13(4):393. PubMed ID: 17415363
[No Abstract] [Full Text] [Related]
47. The long and winding road.
Nat Rev Drug Discov; 2005 Jun; 4(6):443. PubMed ID: 15959946
[No Abstract] [Full Text] [Related]
48. Market watch: upcoming market catalysts in Q1 of 2010.
Rosenthal J
Nat Rev Drug Discov; 2010 Jan; 9(1):11. PubMed ID: 20043022
[No Abstract] [Full Text] [Related]
49. Pharmaceuticals and society: power, promises and prospects.
Gabe J; Williams S; Martin P; Coveney C
Soc Sci Med; 2015 Apr; 131():193-8. PubMed ID: 25727500
[No Abstract] [Full Text] [Related]
50. Companies eye slice of age-related macular degeneration market.
Waltz E
Nat Biotechnol; 2006 Sep; 24(9):1041-2. PubMed ID: 16964195
[No Abstract] [Full Text] [Related]
51. Former pharma pitchman: beware of new drugs. An industry insider advises considering the older options if you need a prescription. Interview by Sarah Baldauf.
Nesi T
US News World Rep; 2008 Nov 3-10; 145(10):64. PubMed ID: 18998444
[No Abstract] [Full Text] [Related]
52. Did Medicare Induce Pharmaceutical Innovation?
Acemoglu D; Cutler D; Finkelstein A; Linn J
Am Econ Rev; 2006 May; 96(2):103-7. PubMed ID: 29131561
[No Abstract] [Full Text] [Related]
53. Predictions and Statistics for the Best-Selling Drugs Globally and in the United States in 2018 and a Look Forward to 2024 Projections.
Lindsley CW
ACS Chem Neurosci; 2019 Mar; 10(3):1115. PubMed ID: 30889957
[No Abstract] [Full Text] [Related]
54. [From the very valuable therapy, to the high cost of a new drug: a growing hiatus].
Scheen AJ
Rev Med Suisse; 2005 Aug; 1(30):1931-2. PubMed ID: 16200935
[No Abstract] [Full Text] [Related]
55. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan.
Honig PK
Clin Pharmacol Ther; 2014 May; 95(5):467-9. PubMed ID: 24747231
[TBL] [Abstract][Full Text] [Related]
56. Market watch: key clinical and regulatory events in Q2 2010.
Hay M
Nat Rev Drug Discov; 2010 Apr; 9(4):261. PubMed ID: 20357797
[No Abstract] [Full Text] [Related]
57. Clinical forecasting in drug development.
Schachter AD; Ramoni MF
Nat Rev Drug Discov; 2007 Feb; 6(2):107-8. PubMed ID: 17342862
[No Abstract] [Full Text] [Related]
58. Drugs that made headlines in 2016.
Keener AB
Nat Med; 2016 Dec; 22(12):1377-1379. PubMed ID: 27923025
[No Abstract] [Full Text] [Related]
59. Pharmacogenomics. Going from genome to pill.
Service RF
Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
[No Abstract] [Full Text] [Related]
60. First Chinese-made biologics slated for human trials in the West.
Deng B
Nat Med; 2014 Jun; 20(6):562. PubMed ID: 24901550
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
